Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Curr Treat Options Gastroenterol. 2015 Mar;13(1):105–120. doi: 10.1007/s11938-014-0042-7

Table 1.

Summary of Selected Clinical Trials of Microbe-Targeted Therapies in IBDs

UC CD Pouchitis

Benefit Trial Design Benefit Trial Design Benefit Trial Design

FMT
+
RCT [18]
Case Series [14,15]
+ Case Series [17]

Antibiotics
Ciprofloxacin/Metronidazole +/− RCT [44,45] + (colonic/perianal) RCT [2628] + RCT [52,53]
Rifaximin RCT [57] + (colonic) RCT [30] RCT [54]
Broad Spectrum + RCT [46,48]

Probiotics
VSL#3 + RCT [67,68] RCT [74] + RCT [80,83]
Other RCT [66] RCT [7173] RCT [85]

Prebiotics RCT [93] RCT [92,95] RCT [96]
HHS Vulnerability Disclosure